Glucose Biosensors Industry: Advances in Glucose Biosensor Technology Revolutionizing Healthcare Industry
Rise of Non-Invasive Glucose Biosensors Industry
Various companies are developing glucose biosensors that can painlessly and continuously monitor glucose levels in interstitial fluid or other body fluids without requiring frequent blood pricking. Notable among these are continuous glucose monitors (CGMs) that use interstitial fluid or other body fluids to measure glucose levels. CGMs eliminate the need for frequent finger pricking while providing real-time glucose readings through the day and night. This brings more convenience to diabetics and helps achieve better glycemic control.
Advancements in CGM Sensing Technology
To make CGMs reliable, accurate and user-friendly, companies are worked on advancing the sensing components. Global Glucose Biosensors Alternatives to enzyme-based electrochemical sensing are being explored. Masimo with its latest CGM, Guardian Sensor, uses a miniaturized optical fluorescent sensor that tracks glucose levels from interstitial fluid. Dexcom with its G6 CGM has also moved from enzyme-based to enzyme-free sensing which is helping to improve accuracy and extend sensor life to up to 10 days. Senseonics has developed an implantable Eversense CGM using fluorescence sensing which can continuously track glucose for up to 6 months from within the body. Advancements in sensor materials, miniaturization of components and sensor calibration algorithms are further enhancing CGM performance.
Transition to Factory Calibration
Historically, users of CGMs had to perform finger prick calibrations multiple times daily to ensure the CGM readings matched the blood glucose readings. This defeated the purpose of painless monitoring. Now, next-gen CGMs are transitioning to factory calibration where the sensors are calibrated in the manufacturing facility before being inserted. This eliminates the need for self-calibration finger pricks. Dexcom’s G6 was the first CGM to implement factory calibration. Senseonics’ Eversense also employs factory calibration. Factory calibration delivers calibration accuracy without user intervention, improving usability and eliminating some pain points of earlier CGMs.
Integration with Automated Insulin Delivery Systems
The highly accurate and reliable data from next-gen CGMs is enabling integration with automated insulin delivery (AID) systems which can help achieve tight glycemic control automatically. Notable examples are Tandem Diabetes’ Control-IQ hybrid closed loop system which integrates with Dexcom G6 CGM and Medtronic’s MiniMed 780G hybrid closed loop system integrated with Guardian CGM. Such integrated systems can basal bolus deliver insulin continuously based on CGM glucose readings without user intervention, helping reduce glycemic variations especially at night. This brings diabetes management a step closer to artificial pancreas solutions. More advanced AID systems relying solely on CGM data without user actions are being targeted by companies.
Growing Glucose Biosensors Industry
The advancements and improved usability of new generation CGMs is driving strong adoption globally. According to a recent report, the global glucose biosensor market valued at $15.9 billion in 2020 and is estimated to grow at an annual rate of 6.9% to reach $26.4 billion by 2028. North America accounts for the largest share currently due to high diabetes prevalence and stringent national diabetes treatment guidelines supporting CGM reimbursement.
In Summary, the Asia Pacific region is witnessing fastest growth rate driven by growing diabetes burden in major countries, increasing healthcare expenditure and favorable insurance coverage for diabetes management devices. As sensing and automation technologies further progress, the glucose biosensor market will continue maintaining double-digit growth rate through next decade, transforming diabetes management modalities worldwide.
Get more insights on This Topic- Glucose Biosensors Industry
Comments
0 comment